Isakova et al. report that kidney transplant recipients on mammalian target of rapamycin (mTOR) inhibitors do not have a lower risk of allograft failure but do have a higher risk of death than those on calcineurin inhibitors. Careful consideration is, therefore, required before converting to mTOR inhibitors to preserve renal function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Webster, A. C., Lee, V. W., Chapman, J. R. & Craig, J. C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 9, 1234–1248 (2006).
Isakova, T. et al. Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Am. J. Transplant. http://dx.doi.org/10.1111/j.1600-61432012.04281.x.
Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392–395 (2009).
Bjedov, I. et al. Mechanisms of life span extension by rapamycin in the fruit fly drosophila melangogaster. Cell Metab. 11, 35–46 (2010).
Lieberthal, W. & Levine, J. S. The role of the mammalian target of rapamycin (mTOR) in renal disease. J. Am. Soc. Nephrol. 20, 2493–2502 (2009).
Flechner, S. M. et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am. J. Transplant. 11, 1633–1644 (2011).
Lieberthal, W. et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am. J. Physiol. Renal Physiol. 281, F693–F706 (2001).
McTaggart, R. A. et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am. J. Transplant. 3, 416–423 (2003).
Ojo, A. O. et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 10, 931–940 (2003).
Kushwaha, S. S. et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J. Heart Lung Transplant. 24, 2129–2136 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Yeh, H., Markmann, J. Are calcineurin inhibitors safer than mTOR inhibitors?. Nat Rev Nephrol 9, 11–13 (2013). https://doi.org/10.1038/nrneph.2012.262
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.262
